HENDERSON, NV / ACCESSWIRE / November 14, 2018 / After a tough year, the prospect that a split congress could be a good thing for healthcare stocks is causing some investors to look again at several smaller healthcare companies that may rebound after being beaten down.
We have listed several below that we feel still may be oversold. Companies with late stage assets and that have upcoming trials are always interesting opportunities. Once those trials are complete, the announcement of positive results could attract significant investor interest.
One such company we like a lot is Delcath Systems, Inc. (DCTH). The company recently announced several major cancer centers have adopted the amended trial protocol for the company's trial in Hepatic-Dominant Ocular Melanoma (The FOCUS Trial) using its product Melphalan/HDS. The company has also initiated a global phase 3 clinical trial in patients with intrahepatic cholangiocarcinoma (the ALIGN Trial). With a global registration trial and a global Phase 3 trial in cancers affecting the liver, now may be the time to do your due diligence on DCTH.
Companies we're highlighting include: Delcath Systems, Inc. (DCTH), Geron Corporation (GERN), ARCA biopharma, Inc. (ABIO), Insmed Incorporated (INSM), and ImmunoGen, Inc. (IMGN).
Delcath Systems, Inc. (DCTH)
Market Cap: $4.59M Share Price: $0.51
Delcath Systems, Inc., announced that patient treatments have begun in the Company's second global US registration trial investigating Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) in the treatment of patients with intrahepatic cholangiocarcinoma (ICC).
The University of Tennessee Health Science Center (UTHSC) in collaboration with Methodist University Hospital (MUH) and West Cancer Center (WCC) in Memphis, Tennessee have enrolled the trial's first patient and treatments have begun by a team led by Dr. Evan S. Glazer. Dr. Glazer, a board certified surgical oncologist, is the principal investigator for the trial at the UTHSC/MUH/WCC location.
Geron Corporation (GERN)
Market Cap: $329.83M Share Price: $1.77
After a rough fall which saw GERN lose over half its value from the beginning of September to the end of September, the company has been on a roll in the past few sessions among many biotechs that are bouncing ahead of the election. GERN recently reported a loss of 3 cents per share for the third quarter of 2018, narrower than the Zacks Consensus Estimates of a loss of 5 cents and the year-ago quarter loss of 4 cents. Quarterly revenues increased 1.2% from the year-ago quarter to $0.17 million, which missed the Zacks Consensus Estimate of $0.22 million. Revenues comprised royalty and license fee revenues received under various non-imetelstat license agreements.
ARCA biopharma, Inc. (ABIO)
Market Cap: $12.11M Share Price: $0.87
ARCA biopharma, a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, started the week on a roll after announcing that data from the Atrial Fibrillation Burden (AFB) substudy of the Phase 2B GENETIC-AF clinical trial have been selected for a poster presentation at the American Heart Association 2018 Scientific Sessions being held November 10-12, 2018 in Chicago. Jonathan Piccini, MD, MHS, FACC, FAHA, FHRS, Associate Professor of Medicine and Director of the Duke Center for Atrial Fibrillation, Duke University will present the data.
Insmed Incorporated (INSM)
Market Cap: $1.34B Share Price: $17.18
INSM announced last week President & CEO of Insmed Inc (INSM) William Lewis bought 15,700 shares of INSM on 11/01/2018 at an average price of $15.9 a share. The total cost of this purchase was $249,630. Insmed Inc is a global biotechnology company. It is focused on developing novel therapies that focus primarily on lung diseases.
ImmunoGen, Inc. (IMGN)
Market Cap: $854.29M Share Price: $5.73
IMGN reported adjusted loss of 31 cents per share for the third quarter of 2018, narrower than the Zacks Consensus Estimate of a loss of 34 cents. The adjusted loss excludes restructuring charges. Moreover, the reported loss of 32 cents was narrower than the year-ago loss of 61 cents per share on higher revenues.
This article was written by Regal Consulting, LLC ("Regal Consulting"). Regal Consulting has agreed to a twelve month term consulting agreement with DCTH dated 8/31/18. The agreement calls for $40,000 in cash, and 15,000 restricted 144 shares of DCTH per month. Issuer agreed to increase monthly cash payment in September to $120,000. All payments were made directly by Delcath Systems, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspecultors.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. DCTH was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.
http://www.regalconsultingllc.com/full legal disclaimer/
Microspeculators.com Full Legal Disclaimer Click Here.
Company Name: Microcap Speculators
Contact Person: Media Manager
Country: United States
SOURCE: ACR Communications,